{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:51:26Z","timestamp":1789386686185,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,5]],"date-time":"2023-11-05T00:00:00Z","timestamp":1699142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,11,5]],"date-time":"2023-11-05T00:00:00Z","timestamp":1699142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s40744-023-00612-7","type":"journal-article","created":{"date-parts":[[2023,11,5]],"date-time":"2023-11-05T15:01:54Z","timestamp":1699196514000},"page":"35-50","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Tofacitinib Efficacy in Patients with Rheumatoid Arthritis and Probable Depression\/Anxiety: Post Hoc Analysis of Phase 3 and 3b\/4 Randomized Controlled Trials"],"prefix":"10.1007","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct00960440","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00847613","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00814307","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00856544","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00853385","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02187055","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Gustavo","family":"Citera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fedra","family":"Irazoque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Madariaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gruben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisy","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Stockert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Santana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas","family":"Ebrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2250-6849","authenticated-orcid":false,"given":"Dario","family":"Ponce de Leon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,5]]},"reference":[{"key":"612_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s41927-019-0092-5","volume":"3","author":"S Peterson","year":"2019","unstructured":"Peterson S, Piercy J, Blackburn S, Sullivan E, Karyekar CS, Li N. The multifaceted impact of anxiety and depression on patients with rheumatoid arthritis. BMC Rheumatol. 2019;3:43.","journal-title":"BMC Rheumatol"},{"key":"612_CR2","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1093\/rheumatology\/ket169","volume":"52","author":"F Matcham","year":"2013","unstructured":"Matcham F, Rayner L, Steer S, Hotopf M. The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2013;52:2136\u201348.","journal-title":"Rheumatology (Oxford)"},{"key":"612_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0217412","volume":"14","author":"M Englbrecht","year":"2019","unstructured":"Englbrecht M, Alten R, Aringer M, et al. New insights into the prevalence of depressive symptoms and depression in rheumatoid arthritis\u2014implications from the prospective multicenter VADERA II study. PLoS ONE. 2019;14: e0217412.","journal-title":"PLoS ONE"},{"key":"612_CR4","unstructured":"World Health Organization. Depression fact sheet. 2023. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/depression. Accessed 7 Feb 2023."},{"key":"612_CR5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1471-244X-12-6","volume":"12","author":"T Covic","year":"2012","unstructured":"Covic T, Cumming SR, Pallant JF, et al. Depression and anxiety in patients with rheumatoid arthritis: prevalence rates based on a comparison of the Depression, Anxiety and Stress Scale (DASS) and the Hospital, Anxiety and Depression Scale (HADS). BMC Psychiatry. 2012;12:6.","journal-title":"BMC Psychiatry"},{"key":"612_CR6","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/art.20474","volume":"51","author":"MM VanDyke","year":"2004","unstructured":"VanDyke MM, Parker JC, Smarr KL, et al. Anxiety in rheumatoid arthritis. Arthritis Rheum. 2004;51:408\u201312.","journal-title":"Arthritis Rheum"},{"key":"612_CR7","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/BOR.0000000000000597","volume":"31","author":"IA Vallerand","year":"2019","unstructured":"Vallerand IA, Patten SB, Barnabe C. Depression and the risk of rheumatoid arthritis. Curr Opin Rheumatol. 2019;31:279\u201384.","journal-title":"Curr Opin Rheumatol"},{"key":"612_CR8","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s40744-020-00217-4","volume":"7","author":"MN Lwin","year":"2020","unstructured":"Lwin MN, Serhal L, Holroyd C, Edwards CJ. Rheumatoid arthritis: the impact of mental health on disease: a narrative review. Rheumatol Ther. 2020;7:457\u201371.","journal-title":"Rheumatol Ther"},{"key":"612_CR9","doi-asserted-by":"publisher","first-page":"20647","DOI":"10.1038\/srep20647","volume":"6","author":"MC Lu","year":"2016","unstructured":"Lu MC, Guo HR, Lin MC, Livneh H, Lai NS, Tsai TY. Bidirectional associations between rheumatoid arthritis and depression: a nationwide longitudinal study. Sci Rep. 2016;6:20647.","journal-title":"Sci Rep"},{"key":"612_CR10","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1136\/annrheumdis-2017-211284","volume":"76","author":"B Michelsen","year":"2017","unstructured":"Michelsen B, Kristianslund EK, Sexton J, et al. Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study. Ann Rheum Dis. 2017;76:1906\u201310.","journal-title":"Ann Rheum Dis"},{"key":"612_CR11","doi-asserted-by":"publisher","first-page":"S180","DOI":"10.1097\/RHU.0000000000001506","volume":"27","author":"CA Isnardi","year":"2021","unstructured":"Isnardi CA, Capelusnik D, Schneeberger EE, et al. Depression is a major determinant of functional capacity in rheumatoid arthritis. J Clin Rheumatol. 2021;27:S180\u20135.","journal-title":"J Clin Rheumatol"},{"key":"612_CR12","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1097\/RHU.0000000000000735","volume":"24","author":"Y Hattori","year":"2018","unstructured":"Hattori Y, Katayama M, Kida D, Kaneko A. Hospital Anxiety and Depression Scale Score is an independent factor associated with the EuroQoL 5-Dimensional Descriptive System in patients with rheumatoid arthritis. J Clin Rheumatol. 2018;24:308\u201312.","journal-title":"J Clin Rheumatol"},{"key":"612_CR13","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1093\/rheumatology\/kev306","volume":"55","author":"F Matcham","year":"2016","unstructured":"Matcham F, Norton S, Scott DL, Steer S, Hotopf M. Symptoms of depression and anxiety predict treatment response and long-term physical health outcomes in rheumatoid arthritis: secondary analysis of a randomized controlled trial. Rheumatology (Oxford). 2016;55:268\u201378.","journal-title":"Rheumatology (Oxford)"},{"key":"612_CR14","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/nrrheum.2016.112","volume":"12","author":"JA Sturgeon","year":"2016","unstructured":"Sturgeon JA, Finan PH, Zautra AJ. Affective disturbance in rheumatoid arthritis: psychological and disease-related pathways. Nat Rev Rheumatol. 2016;12:532\u201342.","journal-title":"Nat Rev Rheumatol"},{"key":"612_CR15","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S2215-0366(18)30255-4","volume":"6","author":"L Nerurkar","year":"2019","unstructured":"Nerurkar L, Siebert S, McInnes IB, Cavanagh J. Rheumatoid arthritis and depression: an inflammatory perspective. Lancet Psychiatry. 2019;6:164\u201373.","journal-title":"Lancet Psychiatry"},{"key":"612_CR16","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1111\/1756-185X.13529","volume":"22","author":"YC Li","year":"2019","unstructured":"Li YC, Chou YC, Chen HC, Lu CC, Chang DM. Interleukin-6 and interleukin-17 are related to depression in patients with rheumatoid arthritis. Int J Rheum Dis. 2019;22:980\u20135.","journal-title":"Int J Rheum Dis"},{"key":"612_CR17","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s12891-016-1083-y","volume":"17","author":"F Matcham","year":"2016","unstructured":"Matcham F, Norton S, Steer S, Hotopf M. Usefulness of the SF-36 Health Survey in screening for depressive and anxiety disorders in rheumatoid arthritis. BMC Musculoskelet Disord. 2016;17:224.","journal-title":"BMC Musculoskelet Disord"},{"key":"612_CR18","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","volume":"381","author":"GR Burmester","year":"2013","unstructured":"Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381:451\u201360.","journal-title":"Lancet"},{"key":"612_CR19","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/art.37816","volume":"65","author":"D van der Heijde","year":"2013","unstructured":"van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65:559\u201370.","journal-title":"Arthritis Rheum"},{"key":"612_CR20","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJMoa1112072","volume":"367","author":"RF van Vollenhoven","year":"2012","unstructured":"van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367:508\u201319.","journal-title":"N Engl J Med"},{"key":"612_CR21","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa1109071","volume":"367","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495\u2013507.","journal-title":"N Engl J Med"},{"key":"612_CR22","doi-asserted-by":"publisher","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","volume":"159","author":"J Kremer","year":"2013","unstructured":"Kremer J, Li Z-G, Hall S, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2013;159:253\u201361.","journal-title":"Ann Intern Med"},{"key":"612_CR23","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","volume":"390","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Mysler E, Hall S, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017;390:457\u201368.","journal-title":"Lancet"},{"key":"612_CR24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315\u201324.","journal-title":"Arthritis Rheum"},{"key":"612_CR25","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.3899\/jrheum.110392","volume":"38","author":"V Strand","year":"2011","unstructured":"Strand V, Boers M, Idzerda L, et al. It\u2019s good to feel better but it\u2019s better to feel good and even better to feel good as soon as possible for as long as possible. Response criteria and the importance of change at OMERACT 10. J Rheumatol. 2011;38:1720\u20137.","journal-title":"J Rheumatol"},{"key":"612_CR26","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.biopsych.2009.09.033","volume":"67","author":"Y Dowlati","year":"2010","unstructured":"Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiat. 2010;67:446\u201357.","journal-title":"Biol Psychiat"},{"key":"612_CR27","doi-asserted-by":"publisher","first-page":"765","DOI":"10.31083\/j.jin2003081","volume":"20","author":"A Wenger","year":"2021","unstructured":"Wenger A, Calabrese P. Comparing underlying mechanisms of depression in multiple sclerosis and rheumatoid arthritis. J Integr Neurosci. 2021;20:765\u201376.","journal-title":"J Integr Neurosci"},{"key":"612_CR28","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1017\/S1461145709009924","volume":"12","author":"RA Khairova","year":"2009","unstructured":"Khairova RA, Machado-Vieira R, Du J, Manji HK. A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. Int J Neuropsychopharmacol. 2009;12:561\u201378.","journal-title":"Int J Neuropsychopharmacol"},{"key":"612_CR29","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.ejphar.2015.06.060","volume":"764","author":"T Fukuyama","year":"2015","unstructured":"Fukuyama T, Tschernig T, Qi Y, Volmer DA, Baumer W. Aggression behaviour induced by oral administration of the Janus-kinase inhibitor tofacitinib, but not oclacitinib, under stressful conditions. Eur J Pharmacol. 2015;764:278\u201382.","journal-title":"Eur J Pharmacol"},{"key":"612_CR30","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1111\/epi.16848","volume":"62","author":"Y Jang","year":"2021","unstructured":"Jang Y, Lee WJ, Lee HS, Chu K, Lee SK, Lee ST. Tofacitinib treatment for refractory autoimmune encephalitis. Epilepsia. 2021;62:e53\u20139.","journal-title":"Epilepsia"},{"key":"612_CR31","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1111\/epi.13387","volume":"57","author":"S Lagarde","year":"2016","unstructured":"Lagarde S, Villeneuve N, Tr\u00e9buchon A, et al. Anti-tumor necrosis factor alpha therapy (adalimumab) in Rasmussen\u2019s encephalitis: an open pilot study. Epilepsia. 2016;57:956\u201366.","journal-title":"Epilepsia"},{"key":"612_CR32","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2147\/JIR.S219586","volume":"13","author":"R Harrington","year":"2020","unstructured":"Harrington R, Al Nokhatha SA, Conway R. JAK inhibitors in rheumatoid arthritis: an evidence-based review on the emerging clinical data. J Inflamm Res. 2020;13:519\u201331.","journal-title":"J Inflamm Res"},{"key":"612_CR33","volume":"2","author":"M Busch-Dienstfertig","year":"2013","unstructured":"Busch-Dienstfertig M, Gonz\u00e1lez-Rodr\u00edguez S. IL-4, JAK-STAT signaling, and pain. JAKSTAT. 2013;2: e27638.","journal-title":"JAKSTAT"},{"key":"612_CR34","doi-asserted-by":"publisher","first-page":"668","DOI":"10.55563\/clinexprheumatol\/e7ayu8","volume":"39","author":"N Crispino","year":"2021","unstructured":"Crispino N, Ciccia F. JAK\/STAT pathway and nociceptive cytokine signalling in rheumatoid arthritis and psoriatic arthritis. Clin Exp Rheumatol. 2021;39:668\u201375.","journal-title":"Clin Exp Rheumatol"},{"key":"612_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.612104","volume":"11","author":"P S\u00fc\u00df","year":"2020","unstructured":"S\u00fc\u00df P, Rothe T, Hoffmann A, Schlachetzki JCM, Winkler J. The joint-brain axis: insights from rheumatoid arthritis on the crosstalk between chronic peripheral inflammation and the brain. Front Immunol. 2020;11: 612104.","journal-title":"Front Immunol"},{"issue":"Suppl 1","key":"612_CR36","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1136\/annrheumdis-2021-eular.176","volume":"80","author":"L Gossec","year":"2021","unstructured":"Gossec L, Citera G, Sellas-Fern\u00e1ndez A, Gruben DC, Valderrama M, G\u00f3mez S. Tofacitinib treatment in patients with psoriatic arthritis and probable depression and\/or anxiety: a post hoc analysis of two Phase 3 clinical trials [abstract]. Ann Rheum Dis. 2021;80(Suppl 1):782.","journal-title":"Ann Rheum Dis"},{"key":"612_CR37","doi-asserted-by":"publisher","first-page":"551","DOI":"10.55563\/clinexprheumatol\/yu55rd","volume":"40","author":"F Behrens","year":"2022","unstructured":"Behrens F, Burmester GR, Feuchtenberger M, et al. Characterisation of depressive symptoms in rheumatoid arthritis patients treated with tocilizumab during routine daily care. Clin Exp Rheumatol. 2022;40:551\u20139.","journal-title":"Clin Exp Rheumatol"},{"key":"612_CR38","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s40744-021-00409-6","volume":"9","author":"GMH Shamail","year":"2022","unstructured":"Shamail GMH, Haridoss M, Natarajan M, Joshua V, Bagepally BS. Association between Janus kinase inhibitors therapy and mental health outcome in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatol Ther. 2022;9:313\u201329.","journal-title":"Rheumatol Ther"},{"key":"612_CR39","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1136\/ard.2008.102509","volume":"69","author":"J Kekow","year":"2010","unstructured":"Kekow J, Moots RJ, Emery P, et al. Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial. Ann Rheum Dis. 2010;69:222\u20135.","journal-title":"Ann Rheum Dis"},{"key":"612_CR40","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/rheumatology\/keq327","volume":"50","author":"J Kekow","year":"2011","unstructured":"Kekow J, Moots R, Khandker R, Melin J, Freundlich B, Singh A. Improvements in patient-reported outcomes, symptoms of depression and anxiety, and their association with clinical remission among patients with moderate-to-severe active early rheumatoid arthritis. Rheumatology (Oxford). 2011;50:401\u20139.","journal-title":"Rheumatology (Oxford)"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-023-00612-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-023-00612-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-023-00612-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T15:30:58Z","timestamp":1705591858000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-023-00612-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,5]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["612"],"URL":"https:\/\/doi.org\/10.1007\/s40744-023-00612-7","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,5]]},"assertion":[{"value":"17 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Gustavo Citera has received speaker, adviser, and\/or investigator fees from AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Gema, Janssen, Novartis, Pfizer Inc, and Sandoz. Rakesh Jain has received research grants from Allergan, Eli Lilly, Lundbeck, Otsuka, Pfizer Inc, Shire, and Takeda; consulting fees or other remuneration from Acadia, Alfasigma, Allergan, Eisai, Eli Lilly, Evidera, Impel, Janssen, Lundbeck, Merck, Neos Therapeutics, Neurocrine Biosciences, Osmotica, Otsuka, Pamlab, Pfizer Inc, Shire, Sunovion, Supernus, Takeda, and Teva; and speaker fees from Alkermes, Allergan, Eli Lilly, Janssen, Lundbeck, Merck, Neos Therapeutics, Neurocrine Biosciences, Otsuka, Pamlab, Pfizer Inc, Shire, Sunovion, Takeda, Teva, and Tris Pharmaceuticals. Fedra Irazoque has received speaker, adviser, and principal investigator fees from AbbVie, Bristol Myers Squibb, Janssen, Pfizer Inc, Roche, and UCB. Hugo Madariaga declares no conflicts of interest. David Gruben, Lisy Wang, Lori Stockert, Karina Santana, Abbas Ebrahim, and Dario Ponce de Leon are employees and stockholders of Pfizer Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All studies were conducted in accordance with the Declaration of Helsinki and International Council for Harmonisation Guidelines for Good Clinical Practice, and were approved by the institutional review board and\/or independent ethics committee for each study center. All patients provided written informed consent. No further ethical approval was required for this post hoc analysis in accordance with the policies of our institutions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}